Discordance between microneurographic and heart- rate spectral indices of sympathetic activity in pulmonary arterial hypertension

Heart

Volumn 95, Issue 9, 2009, Pages 754-758

  McGowan, C L ^a   Swiston, J S ^a   Notarius, C F ^a   Mak, S ^a   Morris, B L ^a   Picton, P E ^a   Granton, J T ^a   Floras, J S ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HYDROXYCHLOROQUINE; LANSOPRAZOLE; LEVOTHYROXINE SODIUM; LORAZEPAM; METHOTREXATE; OMEPRAZOLE; PREDNISONE; RAMIPRIL; ROSUVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART CATHETERIZATION; HEART RATE VARIABILITY; HEART RIGHT ATRIUM PRESSURE; HUMAN; MALE; NEUROGRAPHY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SINUS NODE; SYMPATHETIC NERVE; SYSTOLE; ADRENERGIC SYSTEM; HEART ATRIUM FUNCTION; HEART FAILURE; HEART RATE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REGRESSION ANALYSIS;

ATRIAL FUNCTION, RIGHT; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; SINOATRIAL NODE; SYMPATHETIC NERVOUS SYSTEM;

EID: 65549141178     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.157115     Document Type: Article

References (34)

1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:7-10S.
2. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-65.
3. Ando S, Dajani HR, Floras JS. Frequency domain characteristics of muscle sympathetic nerve activity in heart failure and healthy humans. Am J Physiol 1997;273:R205-12.
4. Floras JS. Alterations in the sympathetic and parasympathetic nervous system in heart failure. In: Mann D, ed. Heart failure: a companion to Braunwald's heart disease. Edinburgh: Harcourt, 2004:247-77.
5. Montano N, Cogliati C, Porta A, et al. Central vagotonic effects of atropine modulate spectral oscillations of sympathetic nerve activity. Circulation 1998;98:1394-9.
6. Notarius CF, Butler GC, Ando S, et al. Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Clin Sci 1999;96:557-65.
7. Pagani M, Montano N, Porta A, et al. Relationship between spectral components of cardiovascular variabilities and direct measures of muscle sympathetic nerve activity in humans. Circulation 1997;95:1441-8.
8. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985;248:H151-3.
9. Saul JP, Rea RF, Eckberg DL, et al. Heart rate and muscle sympathetic nerve variability during reflex changes of autonomic activity. Am J Physiol 1990;258:H713-21.
10. Yamamoto Y, Hughson RL. Coarse-graining spectral analysis: a new method for studying heart rate variability. J Appl Physiol 1991;71:1 143-50.
11. Horner SM, Murphy CF, Coen B, et al. Contribution to heart rate variability by mechanoelectric feedback. Stretch of the sinoatrial node reduces heart rate variability. Circulation 1996;94:1762-7.
12. Notarius CF, Floras JS. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Europace 2001;3:29-38.
13. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308-12.
14. Fauchier L, Babuty D, Melin A, et al. Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 2004;6:181-5.
15. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
16. Sandoval J, Bauerle 0, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994;89:1733-44.
17. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5-12S.
18. Fagius J, Karhuvaara S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension 2007;14:511-17.
19. Glantz SA. Primer of biostatistics. 3rd edn. New York: McGraw-Hill, 1977.
20. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003;177:391-8.
21. Humbert M, Sitbon 0, Chaouat A, et al. Pulmonary arterial hypertension in France. Am J Respir Crit Care Med 2006;173:1023- 30.
22. Butler GC, Ando S, Floras JS. Fractal component of variability of heart rate and systolic blood pressure in congestive heart failure. Clin Sci 1997;92:543-50.
23. Melenovsky V, Simek J, Sperl M, et al. Relation between actual heart rate and autonomic effects of beta blockade in healthy men. Am J Cardiol 2005;95:999-1002.
24. Tulppo MP, Kiviniemi AM, Hautala AJ, et al. Physiological background of the loss of fractal heart rate dynamics. Circulation 2005;112:314-19.
25. Yamamoto Y, Nakamura Y, Sato H, et al. On the fractal nature of heart rate variability in humans: effects of vagal blockade. Am J Physiol 1995;269:R830-7.
26. Yamamoto Y, Hughson RL. On the fractal nature of heart rate variability in humans: effects of data length and B-adrenergic blockade. Am J Physiol 1994;266:R40-9.
27. Yamamoto Y, Fortrat J, Hughson RL. On the fractal nature of heart rate variability in humans: effects of respiratory sinus arrhythmia. Am J Physiol 1995;269:H480-6.
28. Azevedo ER, Newton GE, Floras JS, et al. Reducing cardiac filling pressure lowers cardiac norepinephrine spillover in patients with chronic heart failure. Circulation 2000;101:2053-9.
29. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
30. Chattipakorn N, Incharoen T, Kanlop N, et al. Heart rate variability in myocardial infarction and heart failure. Int J Cardiol 2007;120:289-96.
31. Aronson D, Mittleman M, Burger AJ. Measures of heart period variability as predictors of mortality in hospitalized patients with decompensated congestive heart failure. Am J Cardiol 2004;93:59- 63.
32. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000;21:475-82.
33. LaRovere MT, Mortara A, Pantaleo P, et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90:838-13.
34. Ponikowski P, Anker S, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645-50.